These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 30030111)

  • 21. Fractionated high-dose-rate brachytherapy as monotherapy in prostate cancer: Does implant displacement and its correction influence acute and late toxicity?
    Aluwini S; Busser WM; Baartman LE; Bhawanie A; Alemayehu WG; Boormans JL; Kolkman-Deurloo IK
    Brachytherapy; 2016; 15(6):707-713. PubMed ID: 27364871
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose-rate brachytherapy as monotherapy delivered in two fractions within one day for favorable/intermediate-risk prostate cancer: preliminary toxicity data.
    Ghilezan M; Martinez A; Gustason G; Krauss D; Antonucci JV; Chen P; Fontanesi J; Wallace M; Ye H; Casey A; Sebastian E; Kim L; Limbacher A
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):927-32. PubMed ID: 22197086
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High dose rate brachytherapy as monotherapy for localised prostate cancer.
    Strouthos I; Tselis N; Chatzikonstantinou G; Butt S; Baltas D; Bon D; Milickovic N; Zamboglou N
    Radiother Oncol; 2018 Feb; 126(2):270-277. PubMed ID: 29074079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
    Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
    Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
    Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
    J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined high dose rate brachytherapy and external beam radiotherapy for clinically localised prostate cancer.
    Strouthos I; Chatzikonstantinou G; Zamboglou N; Milickovic N; Papaioannou S; Bon D; Zamboglou C; Rödel C; Baltas D; Tselis N
    Radiother Oncol; 2018 Aug; 128(2):301-307. PubMed ID: 29764692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Term Efficacy and Toxicity of Low-Dose-Rate ¹²⁵I Prostate Brachytherapy as Monotherapy in Low-, Intermediate-, and High-Risk Prostate Cancer.
    Kittel JA; Reddy CA; Smith KL; Stephans KL; Tendulkar RD; Ulchaker J; Angermeier K; Campbell S; Stephenson A; Klein EA; Wilkinson DA; Ciezki JP
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):884-93. PubMed ID: 25962627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose-rate brachytherapy boost for prostate cancer: Comparison of three different fractionation schemes.
    Falk AT; Demontoy S; Chamorey E; Chand ME; Gautier M; Azria D; Zaki S; Chevallier D; Cham Kee DL; Hannoun-Lévi JM
    Brachytherapy; 2017; 16(5):993-999. PubMed ID: 28754301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
    Vicini FA; Kestin LL; Martinez AA
    Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with Hypofractionated External beam radiotherapy for localized prostate cancer: an analysis to determine the correlation between dose-volume histogram parameters in HDR brachytherapy and severity of toxicity.
    Ishiyama H; Kitano M; Satoh T; Kotani S; Uemae M; Matsumoto K; Okusa H; Tabata K; Baba S; Hayakawa K
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):23-8. PubMed ID: 19243900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term Toxicity and Health-related Quality of Life after Single-fraction High Dose Rate Brachytherapy Boost and Hypofractionated External Beam Radiotherapy for Intermediate-risk Prostate Cancer.
    Shahid N; Loblaw A; Chung HT; Cheung P; Szumacher E; Danjoux C; Sankreacha R; Zhang L; Deabreu A; Mamedov A; Morton G
    Clin Oncol (R Coll Radiol); 2017 Jul; 29(7):412-420. PubMed ID: 28190638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone.
    Fang FM; Wang YM; Wang CJ; Huang HY; Chiang PH
    Jpn J Clin Oncol; 2008 Jul; 38(7):474-9. PubMed ID: 18621848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-Term Results of NRG Oncology/RTOG 0321: A Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiation Therapy for Adenocarcinoma of the Prostate.
    Hsu IC; Rodgers JP; Shinohara K; Purdy J; Michalski J; Roach M; Vigneault E; Ivker RA; Pryzant RM; Kuettel M; Taussky D; Gustafson GS; Raben A; Sandler HM
    Int J Radiat Oncol Biol Phys; 2021 Jul; 110(3):700-707. PubMed ID: 33186617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Feasibility and toxicity of a single fraction high-dose-rate brachytherapy followed by a course of EBRT for localized prostate cancer: a retrospective study. The Polyclinique Courlancy experience].
    Mallet F; Wdowczyk D; Bruna A; Villena P; Herard A; Amory JP; Joffroy P; Pangrazzi T
    Cancer Radiother; 2010 Jan; 14(1):11-8. PubMed ID: 20005765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer.
    Ghadjar P; Oesch SL; Rentsch CA; Isaak B; Cihoric N; Manser P; Thalmann GN; Aebersold DM
    Radiat Oncol; 2014 May; 9():122. PubMed ID: 24885327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Five-Year Outcomes of a Single-Institution Prospective Trial of 19-Gy Single-Fraction High-Dose-Rate Brachytherapy for Low- and Intermediate-Risk Prostate Cancer.
    Siddiqui ZA; Gustafson GS; Ye H; Martinez AA; Mitchell B; Sebastian E; Limbacher A; Krauss DJ
    Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1038-1044. PubMed ID: 30771408
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anatomy-based inverse planning dose optimization in HDR prostate implant: a toxicity study.
    Mahmoudieh A; Tremblay C; Beaulieu L; Lachance B; Harel F; Lessard E; Pouliot J; Vigneault E
    Radiother Oncol; 2005 Jun; 75(3):318-24. PubMed ID: 16086913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer.
    Pellizzon AC; Nadalin W; Salvajoli JV; Fogaroli RC; Novaes PE; Maia MA; Ferrigno R
    Radiother Oncol; 2003 Feb; 66(2):167-72. PubMed ID: 12648788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy.
    Morton G; McGuffin M; Chung HT; Tseng CL; Helou J; Ravi A; Cheung P; Szumacher E; Liu S; Chu W; Zhang L; Mamedov A; Loblaw A
    Radiother Oncol; 2020 May; 146():90-96. PubMed ID: 32146259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.